Key regions: United Kingdom, Canada, Japan, Europe, China
Sierra Leone, a country located in West Africa, is experiencing a growing demand for dermatological drugs.
Customer preferences: The increasing awareness of skin diseases and disorders in Sierra Leone has led to a higher demand for dermatological drugs. Skin diseases such as acne, eczema, and psoriasis are becoming more common among the population, leading to an increase in demand for treatments. Additionally, the country's hot and humid climate has led to a rise in skin conditions caused by prolonged sun exposure and insect bites.
Trends in the market: The dermatological drugs market in Sierra Leone is expected to grow due to the rise in demand for both prescription and over-the-counter medications. The market is also seeing an increase in demand for natural and organic products, as consumers are becoming more conscious of the ingredients in their skincare products. Furthermore, the government is increasing its efforts to improve healthcare access and affordability, which is expected to boost the market growth.
Local special circumstances: Sierra Leone has a limited number of dermatologists and healthcare facilities, which has led to a reliance on non-specialist healthcare providers for skin treatments. This has resulted in a higher demand for over-the-counter dermatological drugs, as they are more accessible and affordable than prescription drugs. Additionally, the country's low-income population has limited access to healthcare, leading to a higher demand for affordable dermatological drugs.
Underlying macroeconomic factors: Sierra Leone's economy heavily relies on agriculture, mining, and fishing, which limits the country's ability to invest in healthcare infrastructure. However, the government has implemented policies to improve healthcare access and affordability, which is expected to boost the dermatological drugs market. Additionally, the country's growing population and rising income levels are expected to drive the demand for dermatological drugs in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
